For the year ending 2025-12-31, IRON had -$101,285K decrease in cash & cash equivalents over the period. -$181,326K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -212,184 |
| Depreciation and amortization | 281 |
| Stock-based compensation | 34,340 |
| Amortization/accretion of investment securities | 8,519 |
| Loss from initial consolidation of variable interest entity | -852 |
| Non-cash lease expense | 473 |
| Non-cash interest expense | 837 |
| Other non-cash items | -1 |
| Prepaid expenses and other current assets | 8,922 |
| Accounts payable | 1,070 |
| Accrued external research and development expenses | 4,310 |
| Other accrued expenses | 6,882 |
| Operating lease liabilities | 186 |
| Net cash used in operating activities | -180,393 |
| Purchases of marketable securities | 849,585 |
| Maturities of marketable securities | 456,219 |
| Purchases of property and equipment | 933 |
| Net cash used in investing activities | -394,299 |
| Proceeds from sale of common stock in underwritten offerings, net of issuance costs paid | 440,346 |
| Proceeds from sale of pre-funded warrants in underwritten offerings, net of issuance costs paid | 14,076 |
| Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid | 9,766 |
| Proceeds from issuance of long-term debt, net of issuance costs paid | 0 |
| Payment of debt issuance costs | 0 |
| Proceeds from stock option exercises | 8,641 |
| Contributions from employee stock purchase plan | 578 |
| Net cash provided by financing activities | 473,407 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -101,285 |
| Cash, cash equivalents and restricted cash, beginning of period | 192,672 |
| Cash, cash equivalents and restricted cash, end of period | 91,387 |
Disc Medicine, Inc. (IRON)
Disc Medicine, Inc. (IRON)